Analyst consensus rating
Arcutis Biotherapeutics Analyst Rating: Strong Buy
Direct answer
Arcutis Biotherapeutics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $40.38.
Forecast evidence checked November 12, 2026.
Get free Arcutis Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $28.38
- Average price target
- $40.38
- High price target
- $48.00
- Low price target
- $34.00
- Low target gap
- +19.8%
- Target upside
- +42.3%
- High target gap
- +69.1%
- Target range width
- 49.3%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arcutis Biotherapeutics?
Arcutis Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $40.38.
How far are Arcutis Biotherapeutics's low and high targets from the recorded price?
The low target implies +19.8%, while the high target implies +69.1%.
How many analysts are included in Arcutis Biotherapeutics's consensus?
The verified consensus includes 8 analysts.
How is Arcutis Biotherapeutics's target upside or downside calculated?
The average target of $40.38 is divided by the recorded price of $28.38, then one is subtracted to produce +42.3%. This does not guarantee a future return.
When was Arcutis Biotherapeutics's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.